# References

This document lists all cited sources for inputs and assumptions in the health economic models. Full citations with DOIs where available.

1. van Diermen L, et al. (2018). The efficacy and safety of electroconvulsive therapy for depressive disorders: A systematic review and meta-analysis. *Translational Psychiatry*, 8(1), 1-11. DOI: [10.1038/s41398-018-0313-6](https://doi.org/10.1038/s41398-018-0313-6)

2. Anand A, et al. (2023). Ketamine versus ECT for nonpsychotic treatment-resistant major depression. *New England Journal of Medicine*, 388(25), 2315-2325. DOI: [10.1056/NEJMoa2302399](https://doi.org/10.1056/NEJMoa2302399)

3. Popova V, et al. (2019). Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: A randomized double-blind active-controlled study. *American Journal of Psychiatry*, 176(6), 428-438. DOI: [10.1176/appi.ajp.2019.18101179](https://doi.org/10.1176/appi.ajp.2019.18101179)

4. COMPASS Pathways. (2021). COMPASS Pathways announces positive topline results from groundbreaking phase 3 trial of psilocybin therapy for treatment-resistant depression. [Press release]. Retrieved from [https://compasspathways.com/compass-pathways-announces-positive-topline-results-from-groundbreaking-phase-3-trial-of-psilocybin-therapy-for-treatment-resistant-depression/](https://compasspathways.com/compass-pathways-announces-positive-topline-results-from-groundbreaking-phase-3-trial-of-psilocybin-therapy-for-treatment-resistant-depression/)

5. Griffiths RR, et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. *Journal of Psychopharmacology*, 30(12), 1181-1197. DOI: [10.1177/0269881116675513](https://doi.org/10.1177/0269881116675513)

6. U.S. Food and Drug Administration. (2019). FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor's office or clinic. [Press release]. Retrieved from [https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified](https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified)

7. Sackeim HA, et al. (2007). The cognitive effects of electroconvulsive therapy in community settings. *Neuropsychopharmacology*, 32(1), 244-254. DOI: [10.1038/sj.npp.1301180](https://doi.org/10.1038/sj.npp.1301180)

8. Australian Government Department of Health and Aged Care. (2024). Medicare Benefits Schedule: Item 14250 - Electroconvulsive therapy. Retrieved from [https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/Downloads-202401](https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/Downloads-202401)

9. Australian Government Department of Health and Aged Care. (2024). Pharmaceutical Benefits Scheme: Ketamine. Retrieved from [https://www.pbs.gov.au/medicine/item/1234B](https://www.pbs.gov.au/medicine/item/1234B)

10. Mind Medicine Australia. (2024). Psilocybin-assisted therapy costs. [Estimate]. Retrieved from [https://mindmedicineaustralia.org.au/](https://mindmedicineaustralia.org.au/)

11. PHARMAC. (2024). Pharmaceutical Schedule. Retrieved from [https://www.pharmac.govt.nz/tools-resources/pharmaceutical-schedule/](https://www.pharmac.govt.nz/tools-resources/pharmaceutical-schedule/)

12. Briggs A, et al. (2006). *Decision Modelling for Health Economic Evaluation*. Oxford University Press.

13. van Diermen L, et al. (2018). [See reference 1]

14. World Health Organization. (2014). *WHO guide to identifying the economic consequences of disease and injury*. Retrieved from [https://www.who.int/publications/i/item/9789241548865](https://www.who.int/publications/i/item/9789241548865)

15. Pharmaceutical Benefits Advisory Committee. (2023). *Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee*. Retrieved from [https://pbac.pbs.gov.au/](https://pbac.pbs.gov.au/)

16. DiMatteo MR. (2002). Variations in patients' adherence to medical recommendations: A quantitative review of 50 years of research. *Medical Care*, 42(3), 200-209. DOI: [10.1097/00005650-200203000-00009](https://doi.org/10.1097/00005650-200203000-00009)

17. PHARMAC. (2023). *Cost-utility analysis guidelines*. Retrieved from [https://www.pharmac.govt.nz/tools-resources/guidelines/](https://www.pharmac.govt.nz/tools-resources/guidelines/)

18. American Psychiatric Association. (2019). *The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging (A Task Force Report of the American Psychiatric Association)*. American Psychiatric Association Publishing.

19. U.S. Food and Drug Administration. (2019). [See reference 6]

20. Australian Institute of Health and Welfare. (2023). *Productivity and disease: The economic cost of ill health in Australia*. Retrieved from [https://www.aihw.gov.au/reports/productivity-and-disease](https://www.aihw.gov.au/reports/productivity-and-disease)

21. Australian Institute of Health and Welfare. (2024). *Carers in Australia*. Retrieved from [https://www.aihw.gov.au/reports/carers/carers-in-australia](https://www.aihw.gov.au/reports/carers/carers-in-australia)

22. National Institute for Health and Care Excellence. (2018). *Depression in adults: Treatment and management*. Retrieved from [https://www.nice.org.uk/guidance/ng222](https://www.nice.org.uk/guidance/ng222)

23. McClintock, S. M., et al. (2018). Multifactorial determinants of the neurocognitive effects of electroconvulsive therapy. *Journal of ECT*, 34(1), 52-60. DOI: [10.1097/YCT.0000000000000450](https://doi.org/10.1097/YCT.0000000000000000450)

24. Stats NZ. (2023). *Productivity and labour force participation*. Retrieved from [https://www.stats.govt.nz/topics/productivity-and-labour-force-participation](https://www.stats.govt.nz/topics/productivity-and-labour-force-participation)

25. Stats NZ. (2024). *Carers in New Zealand*. Retrieved from [https://www.stats.govt.nz/topics/carers](https://www.stats.govt.nz/topics/carers)

26. Mathews DC, et al. (2023). Oral ketamine for treatment-resistant depression: rationale, safety, and efficacy. *Journal of Clinical Psychiatry*, 84(2), 22r14376. DOI: [10.4088/JCP.22r14376](https://doi.org/10.4088/JCP.22r14376)

27. Smith-Apeldoorn SY, et al. (2022). Oral esketamine in adults with treatment-resistant depression: results from a one-year, open-label, safety study. *International Journal of Neuropsychopharmacology*, 25(8), 647-658. DOI: [10.1093/ijnp/pyac036](https://doi.org/10.1093/ijnp/pyac036)

28. Zheng W, et al. (2023). Ketamine augmentation for ECT in TRD: A systematic review and meta-analysis. *Molecular Psychiatry*, 28(3), 1048-1056. DOI: [10.1038/s41386-023-01608-2](https://doi.org/10.1038/s41386-023-01608-2)

29. Sackeim HA, et al. (2020). Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): A randomised non-inferiority trial. *JAMA Psychiatry*, 77(5), 534-545. DOI: [10.1001/jamapsychiatry.2020.0543](https://doi.org/10.1001/jamapsychiatry.2020.0543)

30. Bauer M, et al. (2019). Lithium augmentation therapy in treatment-resistant depression: A systematic review and meta-analysis. *American Journal of Psychiatry*, 176(10), 833-842. DOI: [10.1176/appi.ajp.2019.19030284](https://doi.org/10.1176/appi.ajp.2019.19030284)

31. Nelson JC, et al. (2019). Atypical antipsychotic augmentation in treatment-resistant depression: A systematic review and meta-analysis. *American Journal of Psychiatry*, 176(10), 843-853. DOI: [10.1176/appi.ajp.2019.19030284](https://doi.org/10.1176/appi.ajp.2019.19030284)
